NCT00621894已完成2 期
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 23
- 试验地点
- 15
- 主要终点
- Percentage of participants with platelet count >= 50000/µL
研究概览
简要总结
The purpose of this study is to assess the ability of LGD-4665 given daily by mouth to increase platelet counts in the treatment of patients with ITP (immune thrombocytopenic purpura). LGD-4665 increased platelet counts safely and tolerably compared to placebo in healthy volunteers. This study will examine the safety, tolerability and efficacy of 7.5 mg capsules of LGD-4665 to increase platelets compared to placebo, randomized 2:1, during blinded treatment for 6 weeks. Evaluation of platelet counts, bleeding scores and safety parameters will be done weekly. All patients are eligible to continue on active, open LGD-4665 treatment for an additional 12 weeks with optimal adjustment of dose for each patient.
详细描述
This is a Phase IIA study with two parts to the design.
- Part 1 is a randomized, double-blinded, placebo-controlled treatment of 7.5 mg/day LGD-4665 versus placebo in approximately 24 patients with ITP who have been treated with at least one prior therapy for ITP. Patients will be randomized in a ratio of 1:2 (placebo: 7.5 mg/day LGD-4665) for 6 weeks of treatment. Platelet counts, bleeding scores, vital signs, physical exams and laboratory tests will be assessed weekly. Treatment groups will be analyzed for efficacy by the percentage of patients with platelet counts two times baseline and ≥ 50,000/uL at 6 weeks of treatment, and for safety by adverse events, vital signs, physical exams, laboratory tests and use of ITP rescue medications or transfusions.
- Part 2 is an extension of study treatment with open label LGD-4665. All patients who participate in the Part 1 randomized double-blind treatment of this Ph IIA trial are eligible to continue open label treatment with LGD-4665 for up to 3 months at an appropriate dose for the safe maintenance of platelet counts (≥ 50,000/uL to ≤ 200,000/uL). Assessments of effectiveness and safety will be made at 2 and 4 week intervals.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults 18 years or older
- •Diagnosis of ITP for at least 3 months consistent with ASH guidelines
- •Treated with one or more prior therapies for ITP and platelet counts < 30,000/µL or < 50,000/µL if on a stable oral corticosteroid for ≥ 4 weeks, supported by 2 platelet counts in prior 30 days
- •Laboratory results within normal range except for the following analytes
- •Hemoglobin ≥ 10 g/dL
- •Absolute neutrophil counts > 1000/mL
- •ALT ≤ 1.5X ULN
- •AST ≤ 1.5X ULN
- •Creatinine < 1.5X ULN
- •Bilirubin < 1.5X ULN
- •BUN < 1.5X ULN
- •PT < 1.5X ULN
- •aPTT <1.5X ULN
- •Women of child-bearing potential must have a negative serum pregnancy test within 4 days prior to the first dose of study treatment and agree to practice an approved method of contraception or abstinence from sexual intercourse.
- •Willing to sign a written informed consent
- •Exclusion criteria:
- •History of heart attack or cardiovascular disease
- •Known history of arterial or venous thrombosis
- •More than 3 risk factors for thromboembolic events (diabetes, smoker, using oral contraception, using estrogen therapy, hypertriglyceridemia, average cholesterol > 240 mg/dL, treatment for hypertension)
- •Active cancer or a history of bone marrow disorders
- •Women who are pregnant or nursing
- •History of alcohol/drug abuse or dependence within one year
- •Listed medications dosed within:
- •4 weeks of the first dose of the study treatment:
- •Use of Rituximab
- •Use of cytotoxic agents
- •Use of Cyclosporine and other immunomodulators
- •Use of an investigational drug
- •2 weeks of the first dose of the study treatment:
- •Use of Danazol
- •Use of Azathioprine
- •Use of Mycophenolate mofetil and pulsed-dose steroids
- •1 week of the first dose of the study treatment:
- •Use of Anti-D (WinRho®)
- •Use of IVIG
- •Had a platelet transfusion
- •Use of herbal/dietary supplements (excluding vitamins and mineral supplements)
- •3 days of the first dose of the study treatment
- •Use of aspirin, aspirin containing compounds
- •salicylates
- •milk of magnesia
- •non-steroidal anti-inflammatory drugs (unless prescribed for heart disease)
- •History of platelet aggregation that would prevent measurement of platelet counts
- •Known active infection with HIV, hepatitis B, or hepatitis C
- •In the Investigator's opinion, the patient is not able to comply with requirements of the study
排除标准
- 未提供
研究组 & 干预措施
LGD4665
Experimental
LGD-4665: Experimental Thrombopoietin mimetic
干预措施: LGD-4665 (Drug)
Placebo
Placebo Comparator
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Percentage of participants with platelet count >= 50000/µL
时间窗: At Week 6
Response was defined as platelet count \>= 50 x1000/uL for participants without Baseline steroid uses; or platelet counts \>= 50 x1000/uL and doubling the Baseline platelet counts for participants with baseline steroid uses. Confidence interval of response rate was computed using exact method of binomial proportion.
次要结局
- Duration of platelet counts >= 50,000/µL of LGD4665(Up to Week 6)
- Number of participants with time to response by Platelet Counts (platelet counts >= 50,000/µL)(Week 1, 2, 4 and 6 of part 1)
- Change From Baseline to Last Bleeding Observation During Double-Blind Treatment(Day 1 (Baseline) and Week 6)
研究者
研究点 (15)
Loading locations...
相似试验
已完成
2 期
A Safety and Efficacy Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's SyndromeDry Mouth Associated With Sjogren's SyndromeXerostomiaNCT00852839Parion Sciences140
已完成
4 期
A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer SubjectsHealthyNCT00311519Halozyme Therapeutics50
已完成
2 期
A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell CarcinomaBasal Cell CarcinomaNCT01327053Novartis Pharmaceuticals230
终止
1 期
Glyburide vs Placebo as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain Metastases (RAD 1502/UAB 1593)Brain MetastasesCerebral EdemaNCT02460874University of Alabama at Birmingham1
Unknown
2 期
PINGUIN (Postpartum Intervention in Women With Gestational Diabetes Using Insulin)Insulin-dependent Gestational DiabetesNCT01018602Institut fur Diabetesforschung, Munich, Germany140